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Haploinsufficiency of AML1 Affects the
Temporal and Spatial Generation of Hematopoietic
Stem Cells in the Mouse Embryo
specific genes, including IL-3, GM-CSF, CSF-1R, the
subunits of the T cell antigen receptor, myeloperoxi-
dase, and neutrophil elastase (Prosser et al., 1992;
Nuchprayoon et al., 1994; Zhang et al., 1994; Takahashi
et al., 1995). Moreover, the core enhancer sequence has
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A critical role for AML1 in the development of theErasmus University
hematopoietic system was demonstrated by the genera-P.O. Box 1738
tion of mice deficient in this transcription complex3000 DR Rotterdam
(Okuda et al., 1996; Sasaki et al., 1996; Wang et al.,The Netherlands
1996a, 1996b). Null mutations in either AML1 or CBFb
result in an early lethal phenotype with embryos dying
during the midgestational stages of development fromSummary
a complete absence of fetal liver hematopoiesis and
central nervous system hemorrhages (Okuda et al.,The AML1:CBFb transcription factor complex is es-
1996; Wang et al., 1996a). Although primitive yolk sac–sential for definitive hematopoiesis. Null mutations in
derived erythropoiesis appears normal, no definitive he-mouse AML1 result in midgestational lethality with a
matopoietic progenitors of any lineage were presentcomplete lack of fetal liver hematopoiesis. While the
within the fetal liver of these embryos. Analysis of chime-cell autonomous nature and expression pattern of
ric mice generated with AML1-deficient ES cells re-AML1 suggest an intrinsic role for this transcription
vealed that the defect resulting from the loss offactor in the developing hematopoietic system, no di-
AML1:CBFb was intrinsic to the hematopoietic cells andrect link to a functional cell type has been made. Here,
not a result of a defect in the fetal liver microenvironmentwe examine the consequences of AML1 loss in hema-
(Okuda et al., 1996; Wang et al., 1996a). Studies of com-topoietic stem cells (HSC) of the mouse embryo. We
pound mutations for AML1 and CBFb have demon-demonstrate an absolute requirement for AML1 in
strated that AML1 is the limiting subunit for hematopoi-functional HSCs. Moreover, haploinsufficiency results
etic function (Wang et al., 1996b). Moreover, a decreasein a dramatic change in the temporal and spatial distri-
in hematopoietic progenitors has been suggested tobution of HSCs, leading to their early appearance in
result from a haploid dose of AML1:CBFb (Wang et al.,the normal position in the aorta-gonad-mesonephros
1996a, 1996b; Mukouyama et al., 2000). Interestingly,region and also in the yolk sac.
haploinsufficiency has also been shown to result in he-
matopoietic imbalance in humans (Song et al., 1999).
Introduction Germline inactivating mutations in AML1 have been
identified in the autosomal dominant disease familial
The development of the hematopoietic system is regu- thrombocytopenia with a predisposition to acute my-
lated by a series of lineage-specific transcription factors eloid leukemia (Song et al., 1999). These patients present
that control both the formation of hematopoietic stem with a mild decrease in platelets and bone marrow–
cells (HSC) and the lineage commitment and differentia- derived megakaryocyte and myeloid progenitors and
tion of more mature cells. A critical regulator of this develop acute myeloid leukemia at a high frequency in
process is the AML1:CBFb transcription factor complex adulthood. Their underlying hematopoietic defect sug-
(Ogawa et al., 1993a, 1993b; Wang et al., 1993) (reviewed gests a dose-dependent requirement for AML1:CBFb in
in Downing, 1999; Speck et al., 1999). AML1 (also re- normal hematopoiesis. However, how this defect predis-
ferred to as CBFA2, PEBP2, and most recently Runx1) poses to the development of acute myeloid leukemia in
binds to the DNA core enhancer sequence TGTGGT mid to late adult life remains to be determined. Taken
through a central 120 amino acid domain (termed the together, these data suggest that AML1:CBFb functions
runt-homology domain, or RHD, based on homology to in a dose-dependent manner as a critical regulatory
the Drosophila pair-rule protein runt), and its DNA bind- switch that controls the development of hematopoietic
ing affinity is increased by heterodimerizing through the cells of the definitive lineages both in mouse and human.
RHD to CBFb (Meyers et al., 1993; Ogawa et al., 1993b; Where within the hematopoietic cellular hierarchy this
Wang et al., 1993; Speck et al., 1999). AML1 regulates defect occurs remains to be defined.
the transcription of an expanding list of hematopoietic- The recent examination of the expression pattern of
AML1 within the mouse embryo has yielded some in-
sights into possible cellular targets (North et al., 1999).k To whom correspondence should be addressed (e-mail: dzierzak@
At E8.5, expression of AML1 is observed in hematopoi-ch1.fgg.eur.nl).
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the yolk sac. Slightly later, expression is seen in the
endothelial cells and underlying mesenchymal cells of
the ventral portion of the dorsal aorta and the endothelial
cells of the vitelline and umbilical arteries. With further
maturation, AML1 expression appears in the hematopoi-
etic cells that are closely adhering to these endothelial
structures. AML1 is also expressed at high levels in the
hematopoietic cells that develop within the fetal liver,
spleen, and bone marrow in later stage embryos and
adult animals (Simeone et al., 1995; Corsetti and Calabi,
1997; North et al., 1999). The localization of AML1 to
both endothelial and hematopoietic cells within the ini-
tial sites of development of definitive HSCs suggests a
possible role for this transcription factor in the genera-
tion of the hematopoietic system from a common hem-
angioblastic progenitor.
HSCs are known to be at the base of the adult blood
hierarchy. During ontogeny, the first HSCs have been
shown to arise at E10.5 in the region of the mouse em-
bryo body containing the dorsal aorta, gonads, and mes-
onephroi (AGM) (Muller et al., 1994; Medvinsky and
Dzierzak, 1996). More recently, the first HSCs have been
localized to the major arteries of the midgestation mouse
embryo: the dorsal aorta with its surrounding mesen-
chyme and the vitelline and umbilical arteries (de Bruijn
et al., 2000b). The appearance of the first functional
HSCs within the mouse embryo correlates well with the
described pattern of AML1 expression and the onset of
definitive hematopoietic progenitor defects. Thus, it is
of great interest to determine whether the primary defect
in AML1-deficient embryos is in the first functional HSCs
Figure 1. Schematic of Transplantation Protocols
as they arise within the intraembryonic vascular regions.
Explant culture assay. AGMs, yolk sacs (YS), and livers were dis-
We now demonstrate that the AML1:CBFb transcrip- sected from midgestation AML1 wild-type (1/1), heterozygous mu-
tion factor complex is essential for the appearance of tant (1/2), and homozygous mutant (2/2) embryos and cultured
functional HSCs and immature progenitors in the AGM for 3 days as whole tissue explants. Tissues were harvested and
made into a single cell suspension that was injected in irradiatedand yolk sac of midgestational embryos. Moreover, we
adult recipient mice for the CFU-S and HSC assays. Direct assay.show that the generation of HSCs and multipotential
Individual tissues were dissected from midgestation embryos, madeprogenitors is sensitive to the dosage of AML1, with
into a single cell suspension, and directly injected into irradiated
haploinsufficiency not only reducing the total number adult recipients for the HSC assay.
of these cells but also altering their temporal and spatial
development and maintenance within the early embryo.
Taken together, these data suggest that the emergence explants for 3 days as previously described (Medvinsky
of HSCs within the microenvironments of the embryo is and Dzierzak, 1996; Dzierzak and de Bruijn, 2000). Dur-
exquisitely sensitive to the level of AML1 in a develop- ing the culture period, DNA from each embryo was ex-
mental time-dependent manner. amined by PCR for AML1 genotype. Following the incu-
bation period, explants were harvested, made into a
single cell suspension, and the cellular populations as-Results
sessed for CFU-S11 by injecting intravenously into irradi-
ated adult female recipients. Spleens were isolated atAML1 Affects CFU-S Emergence in Midgestation
Hematopoietic Tissues 11 days posttransplantation and CFU-S counted. As
shown in Figure 2, CFU-S11 numbers in wild-type AGMThe emergence of colony forming units-spleen day 11
(CFU-S11) in the normal mouse embryo begins in the and yolk sac increased from E10 to E11, peaking at 3.1
CFU-S11 per embryo tissue equivalent (CFU-S11/ee) inyolk sac and AGM at E9 and reaches maximal numbers
in these tissues between E10–12 (Medvinsky et al., 1993; the AGM and 3.4 CFU-S11/ee in the yolk sac, and then
decreased in number at later ontogenic stages. The firstde Bruijn et al., 2000a). From E11 onward, large numbers
of CFU-S11 can be detected in the fetal liver. To deter- CFU-S11 appeared in the fetal liver at E11 and increased
from 2 CFU-S11/ee at E11 to 5.3 CFU-S11/ee at E12. Inmine whether the AML1 transcription factor is required
for CFU-S production and/or maintenance in these em- contrast to the results with wild-type embryos, no
CFU-S11 were found in any of the hematopoietic tissuesbryonic tissues, we determined the number of CFU-S11
as illustrated in Figure 1. Mice heterozygous for the examined from the AML1 homozygous mutant embryos.
Interestingly, a hemizygous dose of AML1 led to fewerAML1 null mutation (Okuda et al., 1996) were mated,
and yolk sac, AGM, and liver from E10, E11, and E12 CFU-S11 in the AGM, yolk sac, and liver when compared
to wild-type tissues. At E10, hemizygous AML1 AGMsembryos were dissected and cultured as whole tissue
AML1 Haploinsufficiency Affects HSC Development
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Figure 2. Spatial and Temporal Distribution
of CFU-S11 in AML1 Mutant Tissues after 3
Day Organ Explant Culture
CFU-S11 numbers per embryo tissue equiva-
lent are shown for wild-type (1/1), heterozy-
gous (1/-), and homozygous (2/2) tissues.
Each point represents the average number of
CFU-S11/tissue from two to six independent
experiments performed. We injected 1–3 tis-
sue equivalents of cells per recipient. The to-
tal number of injected AGMs; E10 1/1 5 12,
E10 1/2 5 15, E10 2/2 5 6, E11 1/1 5 7,
E11 1/2 5 15, E11 2/2 5 8, E12 1/1 5 3,
E12 1/2 5 2, E12 2/2 5 4; yolk sacs E10
1/1 5 12, E10 1/2 5 18, E10 2/2 5 6,
E11 1/1 5 4, E11 1/2 5 13, E11 2/2 5 8,
E12 1/1 5 3, E12 1/2 5 2, E12 2/2 5 3;
and fetal livers E11 1/1 5 5, E11 1/2 5 12, E12 1/1 5 3, E12 1/2 5 2, E12 2/2 5 4. Range of CFU-S11 numbers/tissue; AGM E10 1/1 5
0–2, E10 1/2 5 0.51–1.25, E11 1/1 5 1–8, E11 1/2 5 0–1.3, E12 1/1 5 1, E12 1/2 5 0–1; yolk sac E10 1/1 5 0–0.83, E10 1/2 5 0.25–0.85,
E11 1/1 5 2–5, E11 1/2 5 0–2.5, E12 1/1 5 1–3.5; liver E11 1/1 5 0.33–4.5, E11 1/2 5 1–3, E12 1/1 5 4.5–7, E12 1/2 5 0–5. Embryos
from E10 contained 32–39 somite pairs, E11 contained 43–49 somite pairs, and E12 contained .50 somite pairs.
and yolk sacs contain comparable CFU-S11 numbers to periment shown in Figure 3A, no donor-derived HSCs
were detected in the peripheral blood DNA of transplantthose in wild-type tissues (0.7 and 0.7 CFU-S11/ee in 1/2
tissues compared to 0.8 and 0.5 CFU-S11/ee in 1/1 recipients that received cells from E12 AGMs, yolk sacs,
or livers derived from AML1 null embryos. By contrast,tissues, respectively). However, at E11, CFU-S11 num-
bers from AML11/2 embryos were decreased 10-fold in nearly all animals transplanted with wild-type cells dem-
onstrated high levels of long-term hematopoietic repop-the AGM (to 0.3 CFU-S11/AGM) and 3.8-fold in the yolk
sac (to 0.9 CFU-S11/yolk sac). Similarly, a decrease in ulation. To further determine if homozygous mutant em-
bryos may contain rare HSCs at earlier ontogenicCFU-S11 number was also observed in the fetal liver of
AML11/- embryos. These data demonstrate that AML1 stages, analysis was also performed on tissues obtained
at E10 and E11. As shown in Table 1 and as previouslyis absolutely required for CFU-S11 production in the AGM
and yolk sac and that a hemizygous dosage of AML1 published (Medvinsky and Dzierzak, 1996), HSCs first
appear in cultures of wild-type AGMs obtained from E10results in overall fewer CFU-S in these tissues from E10
onward, as well as fewer CFU-S in the E12 fetal liver. embryos (8 positive mice/10 recipients) and persist in
this tissue through E11 and E12. In contrast, HSCs doThe decrease in CFU-S numbers at these time points
may reflect a lack of production, expansion, and/or not appear in the yolk sac until 1 day later at E11 (4
positive mice/10 recipients) and first appear in the fetalmaintenance of CFU-S.
liver on the next day at E12 (4 positive mice/4 recipients).
Analysis of tissues from AML1-deficient embryos failedAML1 Is Required for HSC Emergence in Explant
Cultured Midgestation Hematopoietic Tissues to identify the presence of HSCs at any of the develop-
mental times examined. Thus, the AML1/CBFb tran-In the mouse, HSCs first emerge in the E10.5 AGM region
(Muller et al., 1994; Medvinsky and Dzierzak, 1996) and scription factor complex is required for the earliest gen-
eration of HSCs in the E10 and E11 AGM.simultaneously appear in the vitelline and umbilical ar-
teries (de Bruijn et al., 2000b). Subsequently, they can
be found in the yolk sac and fetal liver. Despite extensive Dosage of AML1 Affects the Temporal and Spatial
Emergence of HSCs in the Midgestation Embryocharacterization by cell surface phenotype (Spangrude
et al., 1988, 1991; Sanchez et al., 1996), HSCs can only Since a hemizygous dose of AML1 results in a decrease
in CFU-S numbers in the AGM, yolk sac, and fetal liver,be definitively identified by their functional activity in an
in vivo transplantation assay. Specifically, HSCs in the and in CFC numbers in the fetal liver (Wang et al., 1996a,
1996b) and AGM (Mukouyama et al., 2000), we testedmouse model are most stringently defined by their ability
to contribute for long-term, and at high-levels, to the whether HSCs within the AGM, yolk sac, and fetal liver
might also be affected by limiting doses of AML1. Trans-complete hematopoietic hierarchy in irradiated adult re-
cipients. To examine whether the primary defect in plantations were performed with cultured 1/1 and 1/2
AGM, yolk sac, and fetal liver explants from E10, E11,AML1 mutant embryos is in the earliest emerging HSCs,
we tested for the presence of HSCs in embryonic tissues and E12 embryos, and engraftment was assessed by
testing for donor genetic markers at 1 and greater thanusing this transplantation assay.
Using the protocol shown in Figure 1, we transplanted 4 months posttransplantation. Surprisingly, several dra-
matic differences were observed between wild-type andcells from AML11/1, AML11/-, or AML12/2 embryonic tis-
sues cultured for 3 days as whole organ explants into AML1-haplodeficient tissues (Table 1). First, HSCs ap-
pear prematurely in the E10 yolk sacs from AML11/2irradiated female adult recipients. At 1 month and
greater than 4 months posttransplantation, blood DNA embryos. While no HSCs are found normally in wild-
type yolk sacs (0 positive/10 recipients), 10 out of 17was tested by PCR for the presence of the donor genetic
marker (either the AML1 mutant allele or the YMT, Y recipients of heterozygous AML1 mutant cultured yolk
sacs were positive for the donor genetic marker. Thechromosome-specific marker). In the representative ex-
Immunity
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Table 1. In Vivo Long-Term Hematopoietic Repopulation by
Explant Cultured Transplanted Cells
Emb Day Tissue Explant AML1 Genotype
1/1 1/2 2/2
10 AGM 8a/10b 10/17 0/11
YS 0/10 10/17 0/9
11 AGM 6/10 0/15 0/7
YS 4/10 15/17 0/8
Liver 0/5 7/14 0/4
12 AGM 4/4 0/3 0/4
YS 4/4 2/3 0/4
Liver 4/4 3/4 0/4
9 AGM 0/7 0/8 ND
YS 0/6 0/8 ND
These cumulative data are derived from semiquantitative donor ge-
netic marker PCR analysis of peripheral blood DNA from transplant
recipients at greater than 4 months posttransplantation. a Number
of recipients positive for donor genetic marker. Only recipients con-
taining 10% or greater donor marker signal are considered positive.
b Number of recipients transplanted. Embryos staged as E9 con-
tained 18–29 somite pairs, E10 contained 33–39 somite pairs, E11
contained .41 somite pairs, and E12 contained .50 somite pairs.
E9 data are from two to three experiments in which recipients re-
ceived 1–2 embryo equivalents (ee) of AGM, YS (yolk sac), or fetal
liver cells. E10 data are from five to six experiments in which 1 ee/
recipient was injected. E11 data are from four to seven experiments
in which 0.3–1 ee/recipient was injected. E12 data are from one
experiment in which 0.3 ee/recipient was injected. The low number
of recipients of 1/1 E11 liver cells, and the lower somite pair num-
bers of the 1/1 embryos as compared to the 1/2 embryos used for
the E11 liver transplantation experiments, preclude any evaluation of
the early appearance of HSCs in the 1/2 liver. Previously, we have
reported HSCs in wild-type E11 fetal liver (Muller et al., 1994).
1/2 yolk sac cells are fully potent HSCs, repopulating
all hematopoietic tissues and lineages as well as the
E10 AGM-derived cells (Figure 3B). Moreover, these yolkFigure 3. Donor-Derived Hematopoietic Repopulation of Transplant
sac cells can be serially transplanted into secondaryRecipients
recipients leading to high level, long-term hematopoieticRepresentative PCR analysis of DNA from transplant recipients re-
repopulation (3 positive/3 recipients). The identificationceiving (A) AGM, YS, and liver cells from E12 AML11/1, AML11/2, and
AML12/2 embryos and (B) AML11/2 E10 AGM cells and AML11/2 of potent HSCs in E10 AML11/2 yolk sacs raises the
E10YS cells. Following organ explant culture, tissues were har- possibility that the onset of HSC generation was prema-
vested and injected as a single cell suspension into adult female turely shifted to E9 in the AGM and then rapidly circu-
recipients. DNA was isolated from (A) peripheral blood and (B) hema-
lates into the yolk sac by E10. To address this, we cul-topoietic tissues and specific lineage-sorted hematopoietic cell
tured both AGM and YS from AML11/2 E9 embryos andpopulations of adult recipients at greater than 4 months posttrans-
examined them for the early presence of HSCs by trans-plantation. YMT, Y chromosome-specific oligos were used to detect
donor-derived 1/1 cells in recipients receiving wild type tissues plantation. As shown in Table 1, no HSC activity was
(OP19, 20, 21, 31, 32, 33, 43, 44, and 45). The AML1 mutant (mut) found in either tissue at this point in development, even
allele-specific oligos were used to detect donor-derived 1/2 and when two embryo tissue equivalents were used.
2/2 cells in recipients receiving tissues from 1/2 (OP24, 25, 26,
The second dosage related effect of AML1 is observed35, 37, 38, 47, 48, and 49) and 2/2 (OP27, 29, 30, 39, 40, 41, 51,
at E11. Normally at this point in development, the52, and 53) mutant embryos. The multilineage repopulation analysis
AGM remains a rich source of HSCs, with 6/10 trans-of adults injected with E10 1/2 AGM and YS used the AML1 and
YMT oligos to detect donor cells. The myogenin (MYO) and/or AML1 plant recipients from wild-type AGMs showing long-
wild-type (wt) allele-specific oligos were used to demonstrate the term engraftment. Unexpectedly, when E11 AGMs from
presence of DNA in each sample. Percentage contribution controls AML11/2 embryos were analyzed, no HSC were de-
(0, 1, 10, 50, and 100%) are shown and are used to estimate the
tected (0 positive/15 recipients), suggesting a prematuredegree of repopulation. PB, peripheral blood; BM, bone marrow;
extinction in the ability of the AGM to support the devel-BM-M, bone marrow-myeloid; BM-L, bone marrow-lymphoid; BM-E,
opment/growth of HSCs in AML1/2 embryos. In contrast,bone marrow-erythroid; TH, thymus; LN, lymph node; SP, spleen;
S-M, spleen-myeloid; S-B, spleen-B lymphoid; and S-T, spleen-T HSCs continued to be detected in the yolk sacs (15
lymphoid. positive/17 recipients) and fetal livers from AML1/2 em-
bryos. Moreover, the HSC activity in these latter tissues
persist in the E12 embryos. Taken together, these datalevel of HSC activity in the 1/2 yolk sacs is similar to that
found in 1/2 AGMs at E10 when one tissue equivalent of suggest that haploinsufficiency of AML1 results in an
earlier appearance of HSCs in the E10 yolk sac and acells is injected per recipient. Furthermore, these E10
AML1 Haploinsufficiency Affects HSC Development
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AGM (Table 2). However, direct transplantation of tis-Table 2. In Vivo Long-Term Hematopoietic Repopulation by
Directly Transplanted Cells sues from E11 AML1/2 embryos contrasted with the
results from the explanted tissue in that HSCs wereEmb Day Tissue AML1 Genotype
consistently identified in both the yolk sac (6 positive/6
1/1 1/2 recipients) and AGM (3 positive/5 recipients). The clear
10 AGM 0a/2b 1/2 presence of HSCs in the E11 AGM from AML1/2 em-
YS 0/3 2/3 bryos, but their apparent decrease within this tissue
Liver ND 0/1 following 3 days of in vitro culture (Table 1), suggest a
11 AGM 3/7 3/5 role for AML1 in the maintenance of HSCs in the micro-
YS 3/6 6/6
environment of the AGM. Thus, haploinsufficiency ofLiver 2/5 2/5
AML1 results in a temporal shift in the emergence of
These cumulative data are derived from semiquantitative donor ge- HSCs, resulting in an increase in HSCs at E10 in both
netic marker PCR analysis of peripheral blood DNA from transplant
the AGM and yolk sac, and a later reduction in the abilityrecipients at greater than 4 months posttransplantation. a Number
of the AGM to support HSC maintenance and/orof recipients positive for donor genetic marker. Only recipients con-
expansion.taining 10% or greater donor marker signal are considered positive.
b Number of recipients transplanted. E10 embryos used contained
34–39 somite pairs, and E11 contained 41–46 somite pairs. E10 data Immunosectioning Reveals Changes in Hematopoietic
are from two and E11 data from three independent experiments in Cell Clusters within the E11 AML1 Mutant Embryos
which recipients received one embryo equivalent of AGM, YS (yolk
Descriptive data in chick, mouse, and human embryossac), or fetal liver cells.
have suggested that the origins of definitive hematopoi-
esis are within the hematopoietic clusters that appear
to be emerging from the endothelium of the ventral wall
premature termination of HSC activity in the AGM ex- of the dorsal aorta and the vitelline and umbilical arteries
plants consistent with a change in the balance of HSC (Dieterlen-Lievre and Martin, 1981; Garcia-Porrero et al.,
emergence, migration, and/or maintenance. 1995; Tavian et al., 1996; Jaffredo et al., 1998; North et
al., 1999). While no functional data have directly demon-
strated that these clusters are indeed the source ofDirect Transplantation of AML1 Mutant Midgestation
definitive hematopoietic cells, the first functional HSCsTissues Supports In Vivo Dosage Effects
are identified in these vascular regions (de Bruijn etThe dramatic dosage affect of AML1 on the temporal
al., 2000b). Furthermore, a previous study investigatingappearance and maintenance of HSC activity in the
AML1 expression in mouse embryos using a lacZ markerE10–12 yolk sac and AGM was observed using a 3 day
gene revealed an absence of hematopoietic clusters inwhole organ explant culture step prior to analysis. We
2/2 embryos as compared to 1/2 embryos (North ethave previously demonstrated that during this in vitro
al., 1999). Since we have observed a dosage-relatedculture period an expansion occurs in HSC number.
decrease in functional HSC and CFU-S activity in 1/2However, in order to accurately define the changes in
embryos as compared to 1/1 embryos, we investigatedHSC that are present within the developing embryo ver-
whether hematopoietic cluster numbers and/or charac-sus those arising or modified during the in vitro culture
teristics varied between the three AML1 genotypes.period, we next directly examined cell suspensions from
Embryos were sectioned and stained with antibodyE10 and E11 yolk sacs and AGMs in the transplantation
directed against PECAM-1, which is a marker of endo-assay without using a prior explant culture step (Figure
thelial cells (Vecchi et al., 1994) and early hematopoie-1). Tissues were harvested and prepared individually
tic cells (de Bruijn et al., 1998). Figure 4 shows repre-for injection on a one tissue equivalent to one female
sentative photos of anti-PECAM-1 stained sectionsrecipient basis. At greater than 4 months posttrans-
obtained from E11 embryos of the AML11/1, AML11/-,plantation, peripheral blood DNA was examined for the
and AML12/2 genotype. Wild-type embryos were alwayspresence of the YMT male chromosome marker (for wild-
found to contain several large hematopoietic clusterstype donor HSC repopulation) or the mutant AML1 allele
on the ventral wall of the dorsal aorta and adhering to(for 1/2 HSC repopulation). As shown in Table 2, HSC
the walls of the vitelline and umbilical arteries. Theserepopulation was found in recipients receiving cells from
clusters sometimes appeared with extended stalks. TheE10 1/2 AGM (1 positive/2 recipients) and yolk sac (2
1/2 embryos were found to contain some hematopoi-positive/3 recipients) and is in complete agreement with
etic clusters; however, they were less well defined andthe data using explant cultures of 1/2 E10 tissues (Table
smaller than in the 1/1 embryos. Finally, no hematopoi-1). In contrast, no repopulation was observed when wild-
etic clusters were found in the arteries of 2/2 embryos.type E10 AGM or yolk sac donor cells were used. This
Thus, the dosage of AML1 appears to affect hematopoi-latter result reflects the exceedingly low frequency of
etic cluster formation in the major caudal arteries of theHSCs in the normal E10 AGM (typically requiring the
E11 mouse embryo.expansion achieved during the explant culture for their
detection), and the absence of HSCs from the yolk sac
at this point in development. Thus, a hemizygous dose Discussion
of AML1 leads to an in vivo quantitative increase in HSC
number in both the E10 AGM and yolk sac. The AML1 transcription factor is required for the produc-
tion of all functional HSCs beginning at the time of theirSimilar to the results obtained with in vitro cultured
tissues, direct transplants of E11 wild-type embryos re- first emergence in the AGM region of the E10.5 mouse
embryo and continuing throughout ontogeny and adult-vealed the presence of HSCs in both the yolk sac and
Immunity
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Figure 4. PECAM-1 Staining of Cross Sec-
tions from E11 AML11/1, AML11/2, and
AML12/2 Mouse Embryos
(A) Trunkal cross section through an AML11/1
embryo showing PECAM-1 positive endothe-
lial cells lining the dorsal aorta (boxed-in area)
and the endothelial cells of the umbilical ar-
teries (bottom of the photo). PECAM-1 posi-
tive endothelial cells are also found lining the
other vessels in the lateral body walls and the
mesentery. Large stalk-like PECAM-1 posi-
tive hematopoietic clusters are observed on
the ventral wall of the dorsal aorta (boxed-in
area), and three smaller PECAM-1 positive
hematopoietic clusters are observed on the
lumen of the left umbilical artery as indicated
with arrowheads.
(B) Enlarged view of the dorsal aorta from the
AML11/1 embryo. Three PECAM-1 positive
hematopoietic clusters extend into the lumen
from the ventral wall of the dorsal aorta as
indicated by the arrow.
(C) View of the dorsal aorta from a representative AML11/2 embryo. Two PECAM-1 positive hematopoietic clusters on the ventral wall of the
dorsal aorta are indicated by the arrow.
(D) View of the dorsal aorta from a representative AML12/2 embryo. No PECAM-1 positive hematopoietic clusters were found in the dorsal
aorta or vitelline/umbilical arteries. Magnification of (B), (C), and (D) is 403.
hood. No functional HSCs are found in any of the early Nonetheless, these E10 yolk sac HSCs are as potent as
E10 AGM HSCs, as shown by their ability to long-term,hematopoietic sites, i.e., AGM, yolk sac, or fetal liver
in E10, E11, and E12 homozygous-deficient embryos high level, multilineage repopulate primary recipients,
as well as lead to high level secondary hematopoieticleading to a complete lack of definitive hematopoiesis.
Thus, the underlying defect is cell autonomous to HSCs repopulation. Thus, the appearance of abundant HSC
activity in the yolk sac begs the question of whether theor precursors of HSCs, with the site of the primary defi-
ciency being found first in the AGM region. Recently, yolk sac is capable of autonomous HSC generation,
producing more HSCs under nonphysiologic AML1 con-the other major caudal embryonic arteries, the vitelline
and umbilical arteries, have also been shown to contain centrations, or whether it is seeded prematurely by AGM
generated HSCs (see Figure 5 for model). In the absencefunctional HSCs at E10.5 (de Bruijn et al., 2000b). While
we did not transplant vitelline and umbilical arteries from of the identification of the direct precursor cells to the
adult-repopulating HSCs, and single cell fate mapping,AML1 mutant mice, it is expected that these sites will
also lack functional HSCs. FACS analysis performed it is impossible to distinguish whether these changes in
HSC appearance are a reflection of the dosage affectspreviously by North et al. (1999) on E11.5 AGM regions
from heterozygous and homozygous AML1 mutant em- on the HSC, the direct precursor cell, and/or HSC migra-
tion. However, the dosage of AML1 clearly plays a piv-bryos shows some slight decrease in numbers of AML1
cells positive for HSC marker c-kit and hematopoietic
cell marker CD44. While it is difficult to conclude that
HSCs are completely absent rather than just being non-
functional in the homozygous mutant embryos, the com-
plete absence of hematopoietic clusters in AML1 homo-
zygous mutant embryos suggests that HSCs are not
produced.
A hemizygous dosage effect of AML1 is localized also
to the earliest HSCs in the E10 mouse embryo. Changes
in the temporal and spatial appearance of HSCs in the
yolk sac and AGM are observed. HSCs are found 1
day earlier than normal in haploinsufficient yolk sacs,
appearing at E10, simultaneous to HSC appearance in
the AGM region. Interestingly, direct transplantation of
E10 yolk sac and AGM region cells results in a high Figure 5. Model for Appearance of HSCs in Haploinsufficient Yolk
Sacs at E10frequency of positive recipients, suggesting a quantita-
tive early increase in HSC production in haploinsufficient The unexpected high level presence of HSCs in E10 AML11/2 yolk
sacs suggests that at hemizygous levels, (A) the yolk sac (YS) mayembryos. This may be due to a premature onset in HSC
autonomously generate HSCs simultaneous to HSC generation inproduction; however, no HSC activity was found in E9
the AGM. Alternatively (B), the AGM autonomously generates abun-cultured AGM or yolk sac, suggesting that either there
dant HSCs at E10, and these cells immediately and rapidly migrate
is no shift to an earlier onset of HSC emergence or, to the yolk sac where they can be detected in abundance at E10.
alternatively, that only a minor temporal shift occurs (for Discrimination between these possibilities will require the use of
clonal marking methods and fate mapping.example; by only a few hours or perhaps one cell cycle).
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otal role in the balance of HSC emergence within, and/ et al., 1999): in the hematopoietic clusters lining the
or the migration of HSCs between, the yolk sac and walls of the major arteries, in endothelial cells and some
AGM. mesenchymal cells along the ventral wall of the dorsal
A hemizygous dosage effect of AML1 was also ob- aorta, and in the endothelial cells lining the vitelline and
served in functional HSCs in the E11 AGM region and umbilical arteries. While it is expected that AML1 posi-
in CFU-S11 numbers in all E11 and E12 hematopoietic tive cells from the hematopoietic clusters will contain
embryonic sites. Normal E11 embryos contain an abun- HSC activity, the analysis of AML1 positive endothelial
dance of functional HSCs in 3 day cultured AGM ex- cells or mesenchymal cells for such activity will demon-
plants and directly transplanted AGM region cells. How- strate whether they are direct precursors to HSCs (hem-
ever, HSC activity is prematurely decreased in E11 angioblasts) or elements of the supporting microenvi-
cultured AGM explants from AML1 haploinsufficient em- ronment. It will be interesting to determine whether the
bryos, as compared to wild-type E11 AGM explants, endothelial population or mesenchymal population is
which contain abundant functional HSCs. In preliminary also affected by haploinsufficiency. While our PECAM-1
experiments, we have found that HSC activity is extin- staining data do not reveal any obvious differences in
guished in directly transplanted E12 1/2 AGMs as com- the endothelial cells lining the walls of these vessels,
pared to E12 1/1 AGMs (0.3 ee injected), demonstrating EM studies performed by North et al. (1999) suggest
that this effect also occurs in vivo. Similarly, CFU-S11 some changes in endothelial cell orientation in the ven-
numbers are decreased in E11 haploinsufficient cultured tral aorta wall between 1/2 and 2/2 embryos.
AGM and yolk sac explants and are decreased and ex- Clearly the levels of AML1 are important in maintaining
tinguished in E12 cultured haploinsufficient AGM and the balance of HSC appearance in different embryonic
yolk sac explants, respectively. The cumulative quanti- tissues. While hemizygous levels may promote HSC
tative CFU-S11 decreases in the E11 explants are re- generation prematurely, wild-type levels of AML1 may
flected 1 day later in E12 haploinsufficient liver explants, be required for inhibitory activity—preventing the gener-
which contain approximately half the number of CFU-S ation of HSCs from a direct precursor until a slightly later
compared to wild-type fetal liver. These results suggest developmental time. Alternatively, hemizygous levels of
that fewer CFU-S11 are made in the pre-liver sites and AML1 may prolong HSCs in an undifferentiated state.
thus seed the fetal liver with fewer progenitors. Again, Nonetheless, AML1 is required for HSC production. The
it is not clear whether these defects are intrinsic to AGM regulation of AML1 expression and the mechanism by
HSCs themselves or their direct precursors or may be which this transcription factor acts on the developing
a result of the AML1 dosage on the AGM microenviron- definitive hematopoietic system awaits further investi-
ment (or both). Currently, we are attempting to identify gation. Finally, our results demonstrate that the level of
putative pre-HSC populations by cell surface pheno- AML1 is critical in the formation, maintenance, and/or
type, in vitro culture, and in vivo transplantation, and expansion of HSCs within the microenvironment of the
are developing a chimeric AGM explant culture to test AGM. This function may involve not only cellular path-
for the restoration of AML1/2 HSCs and CFU-S by normal ways intrinsic to the HSCs but also the supporting cells
cells of the AGM microenvironment. within the AGM microenvironment and the interaction
Taken together, the changes due to full or haploinsuffi- between these cellular populations. Importantly, the
ciency of AML1 demonstrate an important role for this lack of a full cohort of HSCs as a result of AML1 haploin-
transcription factor at the earliest time of HSC emer- sufficiency may make the remaining HSCs more prone
gence. Considering the quantitative decreases in HSCs to the acquisition of additional mutations leading to leu-
and CFU-S found in the explant cultures, it is likely that kemia. Thus, further studies on the HSC compartment
the AML1 haploinsufficiency is reflected in the numbers in adult AML1/2 mice should provide important insights
of HSCs and immature progenitors present in the adult. into the mechanism of human leukemogenesis induction
Preliminary data indicate that CFU-S numbers in adult
by AML1 haploinsufficiency (Song et al., 1999).
haploinsufficient bone marrow may be decreased (E. D.,
unpublished data). However, due to complex homeo- Experimental Procedures
static mechanisms operating on the hematopoietic sys-
tem, even a 50% decrease in HSC and CFU-S number Mice and Embryos
AML1 mutant mice were generated as described previously (Okudaappears to be completely compensated in the blood
et al., 1996) and were crossed onto the C57BL/6 background. Toof the adult animal. For example, unlike human AML1
generate embryos, timed matings were set up between AML11/2haploinsufficiency (Song et al., 1999), a defect in platelet
males and 1/2 females or C57BL/6 females. The day of vaginalproduction is not apparent in haploinsufficient mice
plugging was counted as day 0. Animals were housed according to
(Okuda et al., 1996; Wang et al., 1996a). institutional guidelines, with food and water provided ad libitum.
How could AML1 function in HSCs? Studies of the Animal procedures were carried out in compliance with the Stan-
Xenopus AML1 homolog have suggested that this runt dards for Humane Care and Use of Laboratory Animals.
domain protein functions in the specification of hemato-
poietic cells (Tracey et al., 1998). Furthermore, Drosoph- Dissections, Explant Cultures, and Cell Preparation
Pregnant dams were sacrificed by cervical dislocation and embryosila RUNT is required in an early and transient manner in
isolated at E9, E10, E11, and E12, and dissected as previously de-cell fate specification during sex determination, seg-
scribed (Medvinsky et al., 1993; Muller et al., 1994; Dzierzak andmentation, neurogenesis (Dormand and Brand, 1998),
Bruijn, 2000) using watchmakers forceps and 27G needles. Tissue
and hematopoiesis (Lebestky et al., 2000). Thus, a role explants were incubated at the air-medium interface on a permeable
of AML1 in the specification of definitive hematopoiesis membrane filter for 3 days as described in Medvinsky and Dzierzak
is suggested. AML1 expression in midgestation em- (1996) and Dzierzak and de Bruijn (2000). Tissue explants or directly
harvested tissues were collagenase treated (type I, Sigma; finalbryos has been shown in sites of HSC generation (North
Immunity
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concentration 0.12% vol/vol) for 1 hr at 378C in PBS with 10% FCS CORE Grant CA-21765 (J. R. D.), the American Lebanese, Syrian
Associated Charities (ALSAC) of St. Jude Children’s Research Hos-and penicillin/streptomycin followed by 10–20 aspirations into a
pipette to make a single cell suspension. Cells were washed two pital (J. R. D.), NIH grant R01 DK51077-01 (E. D.), Netherlands Re-
search Council 901-08-090 (E. D.), and the Leukemia Society oftimes and resuspended in PBS for injection.
America Scholar Award 103-94 (E. D.).
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